6-methyl-2-(4-methylpiperidin-1-yl)-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4,5-diamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-methyl-2-(4-methylpiperidin-1-yl)-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4,5-diamine
• 化学式: C₁₅H₂₃N₇
• 分子量: 301.39
• InChiKey: HCQMGNQOMSWMNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  95.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Pyrazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20030064982A1

  公开（公告）日：2003-04-03

  This invention describes novel protein kinase inhibitors of formula VII: 1 wherein G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R 1 ; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R y is T-R 3″ ; T is a valence bond or a C 1-4 alkylidene chain; R 3″ is an optionally substituted group selected from C 1-6 aliphatic, C 3-10 carbocyclyl, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms; and R 1 , R 2 , and R 2′ are as described in the specification. The protein kinase are useful for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了式VII:1的新型蛋白激酶抑制剂，其中G为环C或环D；环C选自苯基、吡啶基、嘧啶基、吡嗪基、吡咯烷基或1,2,4-三嗪基环，其中所述的环C具有一个或两个独立选择自-R1的邻位取代基；环D是选自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环；Ry为T-R3″；T为一个价键或C1-4烷基链；R3″为一个可选取代基，选自C1-6脂肪基、C3-10碳环基、C6-10芳基、具有5-10个环原子的杂芳基环或具有5-10个环原子的杂环基环；R1、R2和R2′如说明书所述。这些蛋白激酶对于治疗癌症、糖尿病和阿尔茨海默病等疾病有用。
• TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20120071657A1

  公开（公告）日：2012-03-22

  This invention describes novel triazole compounds of formula IX: wherein Z 1 is nitrogen or CR 9 and Z 2 is nitrogen or CH, provided that at least one of Z 1 and Z 2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R 1 ; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or R x and R y are taken together with their intervening atoms to form a fused ring; R 1 , R 3 , and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.

  该发明描述了式IX的新型三唑类化合物：其中Z1是氮或CR9，Z2是氮或CH，但至少其中一个为氮；G是环C或环D；环C选自苯基、吡啶基、嘧啶基、吡嗪基、吡咯基或1,2,4-三嗪基环，其中所述的环C具有一个或两个独立选择自-R1的邻位取代基；环D是选自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环环；Rx和Ry独立选择自T-R3，或Rx和Ry与它们之间的原子结合形成螺合环；R1、R3和T如说明书所述。该化合物可用作蛋白激酶抑制剂，特别是GSK-3和Aurora的抑制剂，用于治疗糖尿病、癌症和阿尔茨海默病等疾病。
• PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20100256170A1

  公开（公告）日：2010-10-07

  This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了式IV的新型吡唑化合物：其中环D为5-7成员单环或8-10成员双环，选自芳基，杂芳基，杂环基或碳环基；Rx和Ry分别选自T-R3，或与其之间的原子结合形成融合的、不饱和或部分不饱和的5-8成员环，其中有1-3个选自氧、硫或氮的环杂原子；R2、R2'、T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂，特别是aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
• US7390815B2
  申请人：——

  公开号：US7390815B2

  公开（公告）日：2008-06-24
• US7473691B2
  申请人：——

  公开号：US7473691B2

  公开（公告）日：2009-01-06